• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Compugen Reports Fourth Quarter And Full Year 2025 Results

    PR NEWSWIRE

    Compugen Reports Third Quarter 2025 Results

    PR NEWSWIRE

    Compugen To Report Q3 2025 Results On November 10

    PR NEWSWIRE

    Compugen to Share COM701 Ph1 Ovarian Cancer Data at ESMO

    PR NEWSWIRE

    Compugen To Present At SITC 2025

    PR NEWSWIRE

    Compugen to Share COM701 Ph1 Ovarian Cancer Data at ESMO 2025

    PR NEWSWIRE

    Compugen to Release Q2 2025 Results on August 6, 2025

    PR NEWSWIRE

    First Patient Dosed in Compugen`s COM701 Trial for Ovarian Cancer

    PR NEWSWIRE

    Compugen Reports Fourth Quarter and Full Year 2024 Results

    PR NEWSWIRE

    Compugen to Release Q4 & Full Year 2024 Results on March 4, 2025

    PR NEWSWIRE

    Compugen Doses First Patient in Phase 1 Trial for COM503 in Tumors

    PR NEWSWIRE

    Compugen Expands IP Portfolio with Patent for COM902 Combination

    PR NEWSWIRE

    Compugen to Present COM701, COM902 + Pembrolizumab Data at SITC

    PR NEWSWIRE

    Compugen to Present at Single Cell Genomics 2024 Conference

    PR NEWSWIRE

    Compugen Milestone On Dosing In Second Rilvegostomig Phase 3 Trial

    PR NEWSWIRE

    Compugen`s COM701 Triple Combo Shows Activity in mCRC at ASCO

    PR NEWSWIRE

    Compugen Demonstrates Therapeutic Potential of COM503

    PR NEWSWIRE

    Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

    PR NEWSWIRE

    Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

    PR NEWSWIRE

    Compugen`s COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients

    PR NEWSWIRE

    Compugen to Present at Single Cell Genomics 2023 Meeting

    PR NEWSWIRE

    Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902

    PR NEWSWIRE

    Compugen`s COM701 Demonstrates Preliminary Durable Anti-Tumor Activity

    PR NEWSWIRE

    Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll

    PR NEWSWIRE

    Compugen Doses First Patient in Combination COM701, COM902 and Pembrolizumab

    PR NEWSWIRE

    Compugen to Participate in the JMP Securities C-Suite Series

    PR NEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.